• American Society of Breast Disease. The use of magnetic resonance imaging of the breast (MRIB) for screening of women at high risk of breast cancer. Dallas (TX): American Society of Breast Disease; 2004 Jun 28. 5 p. [40 references]

This is the current release of the guideline.

Breast cancer

Risk Assessment
Screening

Family Practice
Internal Medicine
Medical Genetics
Obstetrics and Gynecology
Oncology
Radiation Oncology
Radiology
Surgery

Allied Health Personnel
Physicians

To review current publications and expert opinion on the screening of women at high risk for breast cancer with magnetic resonance imaging of the breast (MRIB)

Women at high risk for breast cancer

Screening of Women at High Risk for Breast Cancer

1. Magnetic resonance imaging of the breast (MRIB) as an adjunct to:
   • Mammography
   • Clinical breast examination
   • Ultrasonography

Sensitivity and specificity of diagnostic tests

Searches of Electronic Databases
Searches of Unpublished Data

Not stated

Not stated

Expert Consensus (Committee)

Not applicable

Review

The Consensus Committee of the American Society for Breast Disease established a subcommittee working group, which reviewed current publications and expert opinion on the screening of women at high risk for breast cancer with magnetic resonance imaging of the breast (MRIB).

Expert Consensus

Not stated

Not applicable

A formal cost analysis was not performed and published cost analyses were not reviewed.

Peer Review

The recommendations were distributed by e-mail to more than 600 members of the American Society of Breast Disease (ASBD) who were invited to comment. The recommendations were then revised to reflect this peer review.

1. Magnetic resonance imaging of the breast (MRIB) is an adjunct to mammography, clinical breast examination, and ultrasonography for breast cancer detection in women at high risk of breast cancer based on family history or BRCA mutations.
2. MRIB is not recommended for breast cancer screening in the general population.
3. Although published studies have evaluated yearly screening in conjunction with mammography, clinical breast examination, and in some cases, ultrasonography, the appropriate screening interval for MRIB is not yet determined.
4. At this time there are no data on the use of MRIB for breast cancer screening of women at high risk based on personal history of breast cancer, previous chest irradiation, lobular carcinoma in situ, atypical hyperplasia, or mutations other than BRCA.
5. Limitations of MRIB are related to technical, professional, and biological factors, as well as availability. Standards related to equipment, scanning protocols, interpretation, MRI-guided biopsies and MRI-guided needle localization are presently under development by the American College of Radiology and other societies. Implementation of these performance standards is expected to continually increase the importance of MRIB.
6. Women should be advised of the benefits and limitations of MRIB.
7. The guideline committee supports and encourages prospective clinical trials of MRIB for surveillance of women at high risk for breast cancer.

None provided

The type of evidence supporting the recommendations is not specifically stated.

Improved screening of women at high risk for breast cancer based on family history or BRCA mutations

Not stated

An implementation strategy was not provided.

Living with Illness
Staying Healthy

Effectiveness
Patient-centeredness

• American Society of Breast Disease. The use of magnetic resonance imaging of the breast (MRIB) for screening of women at high risk of breast cancer. Dallas (TX): American Society of Breast Disease; 2004 Jun 28. 5 p. [40 references]

Not applicable: The guideline was not adapted from another source.

2004 Jun 28

American Society of Breast Disease - Disease Specific Society

American Society of Breast Disease

Expert Committee on Screening of Women at High Risk of Breast Cancer

Committee Members: Amy P. Early, MD, Buffalo Medical Group, Williamsville, New York, Chair; Julio A. Ibarra, MD, Orange Coast Memorial Medical Center, Fountain Valley, California; Kenneth H. Eckert, Jr., MD, Kaleida Breast Center, Women and Children’s Hospital, Buffalo, New York; David M. Euhus, MD, University of Texas Southwestern Medical Center, Dallas, Texas; Steven E. Harms, MD, University of Arkansas, Little Rock, Arkansas; Richard W. Reitherman, MD, Newport Diagnostic Center, La Canada, California; Eva Rubin, MD, Montgomery Radiology Associates, Montgomery, Alabama

Not stated

This is the current release of the guideline.

Electronic copies: Not available at this time.

Print copies: Available from the American Society of Breast Disease, PO Box 140186, Dallas, Texas 75214; Phone: (214) 368-6836

None available

None available

This NGC summary was completed by ECRI on August 16, 2004. The information was verified by the guideline developer on September 14, 2004.

This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions.